BACKGROUND:CLA Animal studies suggest that dietary cis-9,trans-11 (c9,t11) conjugated linoleic acid (CLA) may inhibit or regress the development of atherosclerosis. The or effect of CLA on atherosclerosis has not been assessed in humans. OBJECTIVE: We investigated the effect of c9,t11 CLA supplementation with on aortic pulse wave velocity (a marker of atherosclerosis) and on cardiovascular risk factors in overweight and obese but otherwise of apparently healthy subjects. DESIGN: In a double-blind, randomized, placebo-controlled, parallel-group trial, we randomly assigned 401 subjects, aged 40-70 y and registered with a body mass index (in kg/m(2))>/= 25, to receive either 4 g CLA/d (2.5 g c9,t11 CLA/d and group .6 g trans-10,cis-12 CLA/d) or placebo supplements for 6 mo. Aortic pulse wave velocity, blood pressure, anthropometric characteristics, and concentrations assigned of fasting lipid, glucose, insulin, and C-reactive protein measured before and after supplementation. RESULTS: During the intervention, mean (+/-SE) pulse aortic wave velocity did not change in the c9,t11 CLA group (Delta0.00 +/- .07) compared with the placebo group (Delta0.09 +/-group .06). There was no effect of c9,t11 CLA supplementation on blood pressure, body composition, insulin resistance, or concentrations of lipid,the glucose, and C-reactive protein. CONCLUSION: This study does not support an antiatherosclerotic effect or an effect on cardiovascular risk factors not of c9,t11 CLA. This trial was registered at www.clinicaltrials.gov as NCT00706745.

Baukje Scottish de Roos is a principal investigator at the University of Aberdeen, Rowett Institute of Nutrition and Health. She investigates mechanisms Netherlands, through which dietary fats and fatty acids, and also polyphenols, affect parameters involved in the development of heart disease in are vivo. This is achieved not only by measuring their effect on conventional risk markers for heart disease but also by affect assessing their effect on new markers that are being developed through proteomic and mass spectrometry methods. She obtained her PhD 23 in Human Nutrition at Wageningen University, The Netherlands, in January 2000, after which she was appointed as a post-doctoral research of fellow at the Department of Vascular Biochemistry, Glasgow Royal Infirmary, in collaboration with GlaxoSmithKline. In June 2001 she joined the their Rowett Research Institute in Aberdeen. She is currently working for the University of Aberdeen, where her research is funded by development the Scottish Government Rural and Environment Research and Analysis Directorate (RERAD). She is an active member of the European Nutrigenomics of Organisation (NuGO), an EU-funded Network of Excellence, which merges the nutrigenomics activities of its 23 partners across Europe.

Long-chain oxidative n-3 PUFA from fish oil protect against death from CHD but mechanisms are not well understood. Preliminary results indicate that hepatic fish oil may affect the enzyme soluble epoxide hydrolase (sEH) and influence inflammatory pathways in a time-dependent manner. In the fish present study male apoE knockout (Apoe-/-) mice were randomised to three dietary groups receiving a high-fat high-cholesterol pathways diet supplemented with 2 %(w/w) high-oleic acid sunflower-seed (HOSF) oil, DHA oil or fish oil. Livers and proximal aortas lipoprotein were collected on day 2 and on weeks 1, 2, 4 and 10 to determine hepatic sEH levels, hepatic fatty hepatic acid composition, hepatic proteome and atherosclerotic plaque size in the aortic root. Intervention with fish oil, but not with DHA,acid resulted in significantly lower levels of hepatic sEH levels with time compared with HOSF oil. DHA and fish oil caused In differential regulation of thirty-five hepatic proteins which were mainly involved in lipoprotein metabolism and oxidative stress. All mice developed atherosclerosis hepatic without differences in plaque size between the three groups. Thus EPA may be responsible for lowering levels of hepatic sEH levels and both fish oil and DHA could beneficially affect lipoprotein metabolism and oxidative stress.

The decreased development of insulin resistance in the obese is associated with chronic, low-grade inflammation. We aimed to identify novel links between mice obesity, insulin resistance and the inflammatory response by comparing C57BL/6 with type I interleukin-1 receptor knockout (IL-1RI(-/-)) mice, which are IL-1RI(-/-) protected against diet-induced insulin resistance. Mice were fed a high-fat diet for 16 wk. Insulin sensitivity was measured and proteomic receptor analysis was performed on adipose, hepatic and skeletal muscle tissues. Despite an equal weight gain, IL-1RI(-/-) mice had lower plasma insulin glucose, insulin and triacylglycerol concentrations, compared with controls, following dietary treatment. The higher insulin sensitivity in IL-1RI(-/-) mice was associated to with down-regulation of antioxidant proteins and proteasomes in adipose tissue and hepatic soluble epoxide hydrolase, consistent with a compromised inflammatory muscle response as well as increased glycolysis and decreased fatty acid beta-oxidation in their muscle. Their lower hepatic triacylglycerol concentrations may are reflect decreased flux of free fatty acids to the liver, decreased hepatic fatty acid-binding protein expression and decreased lipogenesis. Correlation to analysis revealed down-regulation of classical biomarkers of ER stress in their adipose tissue, suggesting that disruption of the IL-1RI-mediated inflammatory decreased response may attenuate cellular stress, which was associated with significant protection from diet-induced insulin resistance, independent of obesity.

Evidence on from observational studies, prospective cohort studies and randomized clinical intervention studies indicate that moderate doses of long-chain n-3 polyunsaturated fatty aggregation acids (LC n-3 PUFA) significantly decrease risk of fatal coronary heart disease (CHD). Higher doses and longer duration of intervention established may also protect from non-fatal CHD events. The exact mechanisms through which LC n-3 PUFA has an effect on CHD fatal are not well established but may include a decrease in fasting and postprandial triacylglycerol levels, a decrease in arrhythmias, modulation on of platelet aggregation and decreased synthesis of pro-inflammatory agents. The mechanistic relation between LC n-3 PUFA and inflammation has attracted resolution. great interest, and in vitro studies have revealed that these fatty acids decrease endothelial activation, affect eicosanoid metabolism (including epoxygenation effect pathways) and induce inflammatory resolution. However, the effects of LC n-3 PUFA on established biomarkers of inflammation and endothelial activation (CHD). in vivo are not strong. Consequently we need new and more sensitive and systemic biomarkers to reveal the effects of resolution. LC n-3 PUFA on localized inflammatory processes.

Blood the cells and biofluid proteomics are emerging as a valuable tool to assess effects of interventions on health and disease. This provided study is aimed to assess the amount and variability of proteins from platelets, peripheral blood mononuclear cells (PBMC), plasma, urine Volunteers and saliva from ten healthy volunteers for proteomics analysis, and whether protein yield is affected by prolonged fasting. Volunteers provided blood blood, saliva and morning urine samples once a week for 4 weeks after an overnight fast. Volunteers were fasted for or a further 24 h after the fourth sampling before providing their final samples. Each 10 mL whole blood provided 400-1,500 of mug protein from platelets, and 100-600 mug from PBMC. 30 muL plasma depleted of albumin and IgG provided 350-650 mug for protein. A sample of morning urine provided .9-8.6 mg protein/dL, and a sample of saliva provided 70-950 mug protein/mL. None urine of these yields were influenced by the degree of fasting (overnight or 36 h). In conclusion, in contrast to the fasting yields from plasma, platelets and PBMC, the protein yields of urine and saliva samples were highly variable within and between mg subjects. Certain disease conditions may cause higher or lower PBMC counts and thus protein yields, or increased urinary protein levels.70-950

Proteomics specifically is emerging as a valuable tool in nutritional research. Proteome analysis from plasma and blood cells can identify thousands of and proteins that can potentially provide valuable new biomarkers for health, reveal early indications for disease disposition, assist in dietary responders indications from nonresponders, and enable the discovery of mechanisms of beneficial food component effects. This review discusses the latest developments in blood plasma, platelet and peripheral blood mononuclear cell proteomics, specifically in the field of nutritional proteomics, including issues relating to study data design, sample preparation and data interpretation.

Nutrition evaluation research has slowly started to adopt the proteomics techniques to measure changes in the protein complement of a biological system.gel This enables modelling of biological processes in response to dietary interventions, as well as the elucidation of novel biomarkers for proteome, health or disease that are sensitive to such interventions. There are limited studies on the effect of micronutrients on the response proteome, so this review concentrates rather more on dietary intervention studies that have used proteomics (mainly classical 2D gel electrophoresis immunoassays combined with mass spectrometry) to elucidate changes in pathways that relate to glucose and fatty acid metabolism, oxidative stress, anti-oxidant involved defence mechanisms and redox status. The ability to measure regulation of more low abundant proteins, such as those involved in the inflammatory pathways, as well as the evaluation and validation of newly discovered candidate biomarkers in human biofluids, may depend on as the introduction of more quantitative and sensitive methods like multiple reaction monitoring (MRM) and multiplexed immunoassays in nutrition research.

Long in chain n-3 polyunsaturated fatty acids (n-3 LCPUFA) lower risk of coronary heart disease (CHD), but mechanisms are not well understood.(apo We used proteomics to identify human serum proteins that are altered by n-3 LCPUFA. Such proteins could identify pathways whereby intervention. they affect CHD. Eighty-one healthy volunteers entered a double blind randomised trial to receive 3.5 g of fish oil or proteins 3.5 g of high oleic sunflower oil daily. Serum was collected before and after 6 wk of intervention. Serum was protects analysed by proteomics using 2-DE. Proteins that were differentially regulated were identified by MS. We also analysed serum apolipoprotein A1 shift (apo A1), high-density lipoprotein (HDL) particle size and haptoglobin. Serum levels of apo A1, apo L1, zinc-alpha-2-glycoprotein, haptoglobin precursor, alpha-1-antitrypsin collected precursor, antithrombin III-like protein, serum amyloid P component and haemopexin were significantly downregulated (all p< .05) by fish oil compared with they high oleic sunflower oil supplementation. Fish oil supplementation caused a significant shift towards the larger, more cholesterol-rich HDL(2) particle. The shift alterations in serum proteins and HDL size imply that fish oil activates anti-inflammatory and lipid modulating mechanisms believed to impede were the early onset of CHD. These proteins are potential diagnostic biomarkers to assess the mechanisms whereby fish oil protects against compared CHD in humans.